All In Biotech

Drug Trial Radar · NCT00489476

Staccato Loxapine in Migraine (in Clinic)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Migraine Headache

Last checked: Nov 20, 2026Latest source record: Jul 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Jun 2007

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Alexza Pharmaceuticals, Inc.Not stated
Sponsor type
Not stated
First posted
Jun 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.

Conditions

  • Migraine

Interventions

  • Staccato LoxapineDrug

  • Staccato PlaceboDrug

    Placebo aerosol inhalation (0mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain-relief Response (Pain Severity of NONE or MILD) at 2 HoursTime frame: Baseline and 2 h post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medvadis

    Wellesley Hills, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.